Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.
Grupi 2025. aasta II kvartali auditeerimata konsolideeritud müügitulu kahanes 2024. aasta sama perioodiga võrreldes 9% ja oli kokku €3 440 tuhat (II kv 2024: €3 782 tuhat). 2025. aasta I poolaasta auditeerimata konsolideeritud müügitulu vähenes eelmise aastaga võrreldes samuti 9% ja oli kokku €7 120 tuhat (2024. a I pa: €7 809 tuhat).
Broadridge's faster, cost-efficient access to the ECB's TIPS service is accelerating financial institutions' compliance with new EU Instant Payment regulations
NEW YORK and LONDON and...
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and...
SHANGHAI, July 7, 2025 /PRNewswire/ -- TrinaTracker, the smart solar tracking system provider under Trinasolar (SHA: 688599), announced that it has received a third...
SHANGHAI, July 7, 2025 /CNW/ -- TrinaTracker, the smart solar tracking system provider under Trinasolar (SHA: 688599), announced that it has received a third...
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...
SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases...
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...
TAIPEI, July 7, 2025 /PRNewswire/ -- Advantech is proud to introduce its latest suite of high-performance edge AI compute solutions powered by the Snapdragon®...
On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.
TAIPEI,Taiwan and NEW YORK, July 7, 2025 /PRNewswire/ -- China Airlines (CAL), a Taiwan-based carrier, will begin operations at The New Terminal One at New...